Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RARE | 8-K | bullish | 6/10 | Ultragenyx entered into an asset purchase agreement on October 6, 2026 to sell a Rare Pediatric Disease Priority Review | Oct 7, 2026 |
| BCDA | 8-K | neutral | 3/10 | BioCardia filed an 8-K announcing a poster presentation of the CardiAMP HF II trial design at the HFSA Annual Scientific | Oct 7, 2026 |
| CERO | 8-K | bearish | 6/10 | CERO Therapeutics Holdings has agreed to sell its wholly-owned operating subsidiary (CERo Therapeutics, Inc.) to SRX Glo | Oct 7, 2026 |
| JSPR | 8-K | bullish | 5/10 | Jasper Therapeutics commenced a tender offer to repurchase up to all 12,345,707 outstanding warrants (issued in Sep 2025 | Oct 7, 2026 |
| SYRE | 8-K | bearish | 5/10 | Spyre Therapeutics entered into an underwriting agreement to sell 4,117,648 shares of common stock at $85.00 per share, | Oct 7, 2026 |
| LPCN | 8-K | bullish | 5/10 | Lipocine announced that Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement t | Oct 7, 2026 |
| TTRX | 8-K | neutral | 5/10 | Turn Therapeutics released an updated investor presentation on October 6, 2026, detailing progress across its pipeline i | Oct 6, 2026 |
| RCKT | 8-K | bullish | 7/10 | Rocket Pharmaceuticals entered into a $150M senior secured credit facility with Hercules Capital, receiving an initial $ | Oct 6, 2026 |
| IRLA | 8-K | neutral | 5/10 | Quince Therapeutics stockholders approved the 2026 Equity Incentive Plan (initial reserve of 821,872 shares plus up to 1 | Oct 6, 2026 |
| AURX | 8-K | neutral | 3/10 | Nuo Therapeutics closed the $325,000 Second Funding tranche under its existing Loan Agreement on October 6, 2026, bringi | Oct 6, 2026 |
| SNOA | 8-K | neutral | 3/10 | Sonoma Pharmaceuticals adopted a new Section 382 shareholder rights plan (poison pill) effective October 6, 2026, replac | Oct 6, 2026 |
| BYSI | 8-K | mixed | 6/10 | BeyondSpring completed the sale of its Chinese subsidiary (Bulin) to Biolin Investment Limited on September 30, 2026, re | Oct 6, 2026 |
| BMRN | 8-K | bearish | 6/10 | BioMarin disclosed that its Q3 2026 results will include ~$283M in pre-tax acquired IPR&D charges from the Alesta Therap | Oct 6, 2026 |
| BOLT | 8-K | bearish | 6/10 | Bolt Biotherapeutics amended its lease to accelerate the expiration date to December 31, 2027 (or earlier upon a financi | Oct 6, 2026 |
| CRBU | 8-K | bearish | 7/10 | Caribou Biosciences is discontinuing its two allogeneic CAR-T cell therapy programs (vispa-cel and CB-011), implementing | Oct 6, 2026 |
| KYNB | 8-K | bearish | 8/10 | Kyntra Bio received a delisting determination from Nasdaq on September 30, 2026, for failing to comply with Listing Rule | Oct 6, 2026 |
| NEOG | 8-K | bullish | 6/10 | Neogen reported Q1 FY2027 revenue of $222.8M (+6.5% YoY, +8.1% core growth), beating the $208.2M consensus, but GAAP EPS | Oct 6, 2026 |
| VIVS | 8-K | neutral | 4/10 | VivoSim Labs held its 2026 Annual Meeting on September 30, 2026. Stockholders approved a 3,165,000-share increase to the | Oct 6, 2026 |
| RGEN | 8-K | bullish | 6/10 | Repligen Corporation completed its acquisition of BioLife Solutions on October 6, 2026. BioLife stockholders received $1 | Oct 6, 2026 |
| BIAF | 8-K | bullish | 5/10 | bioAffinity Technologies reported that sales of its CyPath Lung test more than doubled year-over-year through Q3 2026, w | Oct 6, 2026 |
| MAIA | 8-K | neutral | 2/10 | MAIA Biotechnology filed an 8-K furnishing a corporate presentation and summary under Regulation FD, posted to its websi | Oct 6, 2026 |
| AVBP | 8-K | bearish | 7/10 | ArriVent announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did | Oct 6, 2026 |
| PDSB | 8-K | neutral | 3/10 | PDS Biotechnology filed an 8-K announcing a virtual KOL event on October 15, 2026, to discuss Phase 2 clinical outcomes | Oct 6, 2026 |
| TELO | 8-K | neutral | 5/10 | Telomir Pharmaceuticals closed a ~$5.6M PIPE financing on October 5, 2026, issuing 4,843,300 common shares at $1.16/shar | Oct 6, 2026 |
| ENTX | 8-K | neutral | 3/10 | Entera Bio appointed former Gilead and Amgen executive Laura Hamill to its Board of Directors, effective December 1, 202 | Oct 6, 2026 |
| REGN | 8-K | bullish | 7/10 | Regeneron and Sanofi expanded their antibody collaboration via the Sixth Amendment, with Sanofi paying a $1.0B upfront a | Oct 6, 2026 |
| SXTP | 8-K | neutral | 5/10 | 60 Degrees Pharmaceuticals announced it will conclude enrollment in its randomized severe babesiosis study at 30 patient | Oct 6, 2026 |
| KAPA | 8-K | bullish | 6/10 | Kairos Pharma reported positive interim Phase 2 data for ENV-105 (carotuximab) in metastatic castration-resistant prosta | Oct 6, 2026 |
| INDV | 8-K | neutral | 3/10 | Indivior filed an 8-K supplementing its joint proxy statement/prospectus for the pending merger with Supernus, adding su | Oct 6, 2026 |
| ADIA | 8-K | neutral | 4/10 | Adia Med, Inc. completed the sale of a 30% membership interest in its subsidiary Adia Labs LLC to Live Oak Health LLC (d | Oct 5, 2026 |